126
|
Yu JS. Profile. Hum Vaccin Immunother 2012; 8:1745. [PMID: 23817320 PMCID: PMC3656060 DOI: 10.4161/hv.23357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
127
|
Patil CG, Nuño M, Elramsisy A, Mukherjee D, Carico C, Dantis J, Hu J, Yu JS, Fan X, Black KL, Bannykh SI. High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era. Neuro Oncol 2012; 15:104-11. [PMID: 23115159 DOI: 10.1093/neuonc/nos272] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
We investigated whether high levels of activated mitogen-activated protein kinase (p-MAPK) were associated with poor survival among patients with newly diagnosed glioblastoma during the temozolomide era. Nuclear p-MAPK expression of 108 patients with GBM was quantified and categorized in the following levels: low (0%-10%), medium (11%-40%), and high (41%-100%). Independent predictors of overall survival were determined using a multivariate Cox proportional hazards model. Our study included 108 patients with newly diagnosed GBM. Median age was 65 years, and 74% had high Karnofsky performance status (KPS ≥ 80). Median overall survival among all patients was 19.5 months. Activated MAPK expression levels of <10%, 11%-40%, and ≥ 41% were observed in 33 (30.6%), 37 (34.3%), and 38 (35.2%) patients, respectively. Median survival for low, medium, and high p-MAPK expression was 32.4, 18.2, and 12.5 months, respectively. Multivariate analysis showed 2.4-times hazard of death among patients with intermediate p-MAPK than low p-MAPK expression (hazard ratio [HR], 2.4; P = .02); high-expression patients were 3.9 times more likely to die, compared with patients with low p-MAPK (HR, 3.9; P = .007). Patients aged ≥ 65 years (HR, 2.8; P = .002) with KPS < 80 (HR, 3.1; P = .0003) and biopsy or partial resection (HR, 1.9; P = .02) had higher hazard of death. MGMT and PTEN expression were not associated with survival differences. This study provides quantitative means of evaluating p-MAPK in patients with GBM. It confirms the significant and independent prognostic relevance of p-MAPK in predicting survival of patients with GBM treated in the temozolomide era and highlights the need for therapies targeting the p-MAPK oncogenic pathway.
Collapse
|
128
|
Ablikim M, Achasov MN, Ambrose DJ, An FF, An Q, An ZH, Bai JZ, Ferroli RB, Ban Y, Becker J, Berger N, Bertani MB, Bian JM, Boger E, Bondarenko O, Boyko I, Briere RA, Bytev V, Cai X, Calcaterra AC, Cao GF, Chang JF, Chelkov G, Chen G, Chen HS, Chen JC, Chen ML, Chen SJ, Chen Y, Chen YB, Cheng HP, Chu YP, Cronin-Hennessy D, Dai HL, Dai JP, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, Ding WM, Ding Y, Dong LY, Dong MY, Du SX, Fang J, Fang SS, Fava L, Feldbauer F, Feng CQ, Fu CD, Fu JL, Gao Y, Geng C, Goetzen K, Gong WX, Gradl W, Greco M, Gu MH, Gu YT, Guan YH, Guo AQ, Guo LB, Guo YP, Han YL, Hao XQ, Harris FA, He KL, He M, He ZY, Held T, Heng YK, Hou ZL, Hu HM, Hu JF, Hu T, Huang B, Huang GM, Huang JS, Huang XT, Huang YP, Hussain T, Ji CS, Ji Q, Ji XB, Ji XL, Jia LK, Jiang LL, Jiang XS, Jiao JB, Jiao Z, Jin DP, Jin S, Jing FF, Kalantar-Nayestanaki N, Kavatsyuk M, Kuehn W, Lai W, Lange JS, Leung JKC, Li CH, Li C, Li C, Li DM, Li F, Li G, Li HB, Li JC, Li K, Li L, Li NB, Li QJ, Li SL, Li WD, Li WG, Li XL, Li XN, Li XQ, Li XR, Li ZB, Liang H, Liang YF, Liang YT, Liao GR, Liao XT, Liu BJ, Liu BJ, Liu CL, Liu CX, Liu CY, Liu FH, Liu F, Liu F, Liu H, Liu HB, Liu HH, Liu HM, Liu HW, Liu JP, Liu K, Liu K, Liu KY, Liu PL, Liu SB, Liu X, Liu XH, Liu YB, Liu Y, Liu ZA, Liu Z, Liu Z, Loehner H, Lu GR, Lu HJ, Lu JG, Lu QW, Lu XR, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Lv M, Ma CL, Ma FC, Ma HL, Ma QM, Ma S, Ma T, Ma XY, Ma Y, Maas FE, Maggiora M, Malik QA, Mao H, Mao YJ, Mao ZP, Messchendorp JG, Min J, Min TJ, Mitchell RE, Mo XH, Morales Morales C, Motzko C, Muchnoi NY, Nefedov Y, Nicholson C, Nikolaev IB, Ning Z, Olsen SL, Ouyang Q, Pacetti SP, Park JW, Pelizaeus M, Peters K, Ping JL, Ping RG, Poling R, Prencipe E, Pun CSJ, Qi M, Qian S, Qiao CF, Qin XS, Qin Y, Qin ZH, Qiu JF, Rashid KH, Rong G, Ruan XD, Sarantsev A, Schulze J, Shao M, Shen CP, Shen XY, Sheng HY, Shepherd MR, Song XY, Spataro S, Spruck B, Sun DH, Sun GX, Sun JF, Sun SS, Sun XD, Sun YJ, Sun YZ, Sun ZJ, Sun ZT, Tang CJ, Tang X, Thorndike EH, Tian HL, Toth D, Ulrich MU, Varner GS, Wang B, Wang BQ, Wang K, Wang LL, Wang LS, Wang M, Wang P, Wang PL, Wang Q, Wang QJ, Wang SG, Wang XF, Wang XL, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZG, Wang ZY, Wei DH, Weidenkaff P, Wen QG, Wen SP, Werner MW, Wiedner U, Wu LH, Wu N, Wu SX, Wu W, Wu Z, Xia LG, Xiao ZJ, Xie YG, Xiu QL, Xu GF, Xu GM, Xu H, Xu QJ, Xu XP, Xu Y, Xu ZR, Xue F, Xue Z, Yan L, Yan WB, Yan YH, Yang HX, Yang T, Yang Y, Yang YX, Ye H, Ye M, Ye MH, Yu BX, Yu CX, Yu JS, Yu SP, Yuan CZ, Yuan WL, Yuan Y, Zafar AA, Zallo AZ, Zeng Y, Zhang BX, Zhang BY, Zhang CC, Zhang DH, Zhang HH, Zhang HY, Zhang J, Zhang JG, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang L, Zhang SH, Zhang TR, Zhang XJ, Zhang XY, Zhang Y, Zhang YH, Zhang YS, Zhang ZP, Zhang ZY, Zhao G, Zhao HS, Zhao JW, Zhao KX, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao TC, Zhao XH, Zhao YB, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zheng ZP, Zhong B, Zhong J, Zhou L, Zhou XK, Zhou XR, Zhu C, Zhu K, Zhu KJ, Zhu SH, Zhu XL, Zhu XW, Zhu YM, Zhu YS, Zhu ZA, Zhuang J, Zou BS, Zou JH, Zuo JX. Evidence for the direct two-photon transition from ψ(3686) to J/ψ. PHYSICAL REVIEW LETTERS 2012; 109:172002. [PMID: 23215179 DOI: 10.1103/physrevlett.109.172002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/01/2012] [Indexed: 06/01/2023]
Abstract
The two-photon transition ψ(3686)→γγJ/ψ is studied in a sample of 1.06×10(8) ψ(3686) decays collected by the BESIII detector. The branching fraction is measured to be (3.1±0.6(stat)(-1.0)(+0.8)(syst))×10(-4) using J/ψ→e(+)e(-) and J/ψ→μ(+)μ(-) decays, and its upper limit is estimated to be 4.5×10(-4) at the 90% confidence level. This work represents the first measurement of a two-photon transition among charmonium states. The orientation of the ψ(3686) decay plane and the J/ψ polarization in this decay are also studied. In addition, the product branching fractions of sequential E1 transitions ψ(3686)→γχ(cJ) and χ(cJ)→γJ/ψ(J=0,1,2) are reported.
Collapse
|
129
|
Patil CG, Yi A, Elramsisy A, Hu J, Mukherjee D, Irvin DK, Yu JS, Bannykh SI, Black KL, Nuño M. Prognosis of patients with multifocal glioblastoma: a case-control study. J Neurosurg 2012; 117:705-11. [DOI: 10.3171/2012.7.jns12147] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Object
The prognosis of patients with glioblastoma who present with multifocal disease is not well documented. The objective of this study was to determine whether multifocal disease on initial presentation is associated with worse survival.
Methods
The authors retrospectively reviewed records of 368 patients with newly diagnosed glioblastoma and identified 47 patients with multifocal tumors. Each patient with a multifocal tumor was then matched with a patient with a solitary glioblastoma on the basis of age, Karnofsky Performance Scale (KPS) score, and extent of resection, using a propensity score matching methodology. Radiation and temozolomide treatments were also well matched between the 2 cohorts. Kaplan-Meier estimates and log-rank tests were used to compare patient survival.
Results
The incidence of multifocal tumors was 12.8% (47/368). The median age of patients with multifocal tumors was 61 years, 76.6% had KPS scores ≥ 70, and 87.2% underwent either a biopsy or partial resection of their tumors. The 47 patients with multifocal tumors were almost perfectly matched on the basis of age (p = 0.97), extent of resection (p = 1.0), and KPS score (p = 0.80) compared with 47 patients with a solitary glioblastoma. Age (>65 years), partial resection or biopsy, and low KPS score (<70) were associated with worse median survival within the multifocal group. In the multifocal group, 19 patients experienced tumor progression on postradiation therapy MRI, compared with 11 patients (26.8%) with tumor progression in the unifocal group (p = 0.08). Patients with multifocal tumors experienced a significantly shorter median overall survival of 6 months (95% CI 4–10 months), compared with the 11-month median survival (95% CI 10–19 months) of the matched solitary glioblastoma group (p = 0.02, log-rank test). Two-year survival rates were 4.3% for patients with multifocal tumors and 29.0% for the unifocal cohort. Patients with newly diagnosed multifocal tumors were found to have an almost 2-fold increase in the hazard of death compared with patients with solitary glioblastoma (hazard ratio 1.8, 95% CI 1.1–3.1; p = 0.02). Tumor samples were analyzed for expression of phosphorylated mitogen-activated protein kinase, phosphatase and tensin homolog, O6-methylguanine-DNA methyltransferase, laminin β1 and β2, as well as epidermal growth factor receptor amplification, and no significant differences in expression profile between the multifocal and solitary glioblastoma groups was found.
Conclusions
Patients with newly diagnosed multifocal glioblastoma on presentation experience significantly worse survival than patients with solitary glioblastoma. Patients with multifocal tumors continue to pose a therapeutic challenge in the temozolomide era and magnify the challenges faced while treating patients with malignant gliomas.
Collapse
|
130
|
Milanesi A, Lee JW, Li Z, Da Sacco S, Villani V, Cervantes V, Perin L, Yu JS. β-Cell regeneration mediated by human bone marrow mesenchymal stem cells. PLoS One 2012; 7:e42177. [PMID: 22879915 PMCID: PMC3413696 DOI: 10.1371/journal.pone.0042177] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2012] [Accepted: 07/04/2012] [Indexed: 12/11/2022] Open
Abstract
Bone marrow mesenchymal stem cells (BMSCs) have been shown to ameliorate diabetes in animal models. The mechanism, however, remains largely unknown. An unanswered question is whether BMSCs are able to differentiate into β-cells in vivo, or whether BMSCs are able to mediate recovery and/or regeneration of endogenous β-cells. Here we examined these questions by testing the ability of hBMSCs genetically modified to transiently express vascular endothelial growth factor (VEGF) or pancreatic-duodenal homeobox 1 (PDX1) to reverse diabetes and whether these cells were differentiated into β-cells or mediated recovery through alternative mechanisms. Human BMSCs expressing VEGF and PDX1 reversed hyperglycemia in more than half of the diabetic mice and induced overall improved survival and weight maintenance in all mice. Recovery was sustained only in the mice treated with hBMSCs-VEGF. However, de novo β-cell differentiation from human cells was observed in mice in both cases, treated with either hBMSCs-VEGF or hBMSCs- PDX1, confirmed by detectable level of serum human insulin. Sustained reversion of diabetes mediated by hBMSCs-VEGF was secondary to endogenous β-cell regeneration and correlated with activation of the insulin/IGF receptor signaling pathway involved in maintaining β-cell mass and function. Our study demonstrated the possible benefit of hBMSCs for the treatment of insulin-dependent diabetes and gives new insight into the mechanism of β-cell recovery after injury mediated by hBMSC therapy.
Collapse
|
131
|
Yu JS, Lee BS, Clond M, Ley E. 149 Nanoprodrug Accumulates in Experimental Traumatic Brain Injury. Neurosurgery 2012. [DOI: 10.1227/01.neu.0000417739.47418.84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
132
|
Ablikim M, Achasov MN, Ambrose DJ, An FF, An Q, An ZH, Bai JZ, Ban Y, Becker J, Berger N, Bertani M, Bian JM, Boger E, Bondarenko O, Boyko I, Briere RA, Bytev V, Cai X, Calcaterra A, Cao GF, Chang JF, Chelkov G, Chen G, Chen HS, Chen JC, Chen ML, Chen SJ, Chen Y, Chen YB, Cheng HP, Chu YP, Cronin-Hennessy D, Dai HL, Dai JP, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, Ding WM, Ding Y, Dong LY, Dong MY, Du SX, Fang J, Fang SS, Fava L, Feldbauer F, Feng CQ, Ferroli RB, Fu CD, Fu JL, Gao Y, Geng C, Goetzen K, Gong WX, Gradl W, Greco M, Gu MH, Gu YT, Guan YH, Guo AQ, Guo LB, Guo YP, Han YL, Hao XQ, Harris FA, He KL, He M, He ZY, Held T, Heng YK, Hou ZL, Hu HM, Hu JF, Hu T, Huang B, Huang GM, Huang JS, Huang XT, Huang YP, Hussain T, Ji CS, Ji Q, Ji XB, Ji XL, Jia LK, Jiang LL, Jiang XS, Jiao JB, Jiao Z, Jin DP, Jin S, Jing FF, Kalantar-Nayestanaki N, Kavatsyuk M, Kuehn W, Lai W, Lange JS, Leung JKC, Li CH, Li C, Li C, Li DM, Li F, Li G, Li HB, Li JC, Li K, Li L, Li NB, Li QJ, Li SL, Li WD, Li WG, Li XL, Li XN, Li XQ, Li XR, Li ZB, Liang H, Liang YF, Liang YT, Liao GR, Liao XT, Liu BJ, Liu BJ, Liu CL, Liu CX, Liu CY, Liu FH, Liu F, Liu F, Liu H, Liu HB, Liu HH, Liu HM, Liu HW, Liu JP, Liu KY, Liu K, Liu K, Liu PL, Liu SB, Liu X, Liu XH, Liu Y, Liu YB, Liu ZA, Liu Z, Liu Z, Loehner H, Lu GR, Lu HJ, Lu JG, Lu QW, Lu XR, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Lv M, Ma CL, Ma FC, Ma HL, Ma QM, Ma S, Ma T, Ma XY, Ma Y, Maas FE, Maggiora M, Malik QA, Mao H, Mao YJ, Mao ZP, Messchendorp JG, Min J, Min TJ, Mitchell RE, Mo XH, Morales Morales C, Motzko C, Muchnoi NY, Nefedov Y, Nicholson C, Nikolaev IB, Ning Z, Olsen SL, Ouyang Q, Pacetti S, Park JW, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Poling R, Prencipe E, Pun CSJ, Qi M, Qian S, Qiao CF, Qin XS, Qin Y, Qin ZH, Qiu JF, Rashid KH, Rong G, Ruan XD, Sarantsev A, Schaefer BD, Schulze J, Shao M, Shen CP, Shen XY, Sheng HY, Shepherd MR, Song XY, Spataro S, Spruck B, Sun DH, Sun GX, Sun JF, Sun SS, Sun XD, Sun YJ, Sun YZ, Sun ZJ, Sun ZT, Tang CJ, Tang X, Thorndike EH, Tian HL, Toth D, Ullrich M, Varner GS, Wang B, Wang BQ, Wang K, Wang LL, Wang LS, Wang M, Wang P, Wang PL, Wang Q, Wang QJ, Wang SG, Wang XF, Wang XL, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZG, Wang ZY, Wei DH, Weidenkaff P, Wen QG, Wen SP, Werner M, Wiedner U, Wu LH, Wu N, Wu SX, Wu W, Wu Z, Xia LG, Xiao ZJ, Xie YG, Xiu QL, Xu GF, Xu GM, Xu H, Xu QJ, Xu XP, Xu Y, Xu ZR, Xue F, Xue Z, Yan L, Yan WB, Yan YH, Yang HX, Yang T, Yang Y, Yang YX, Ye H, Ye M, Ye MH, Yu BX, Yu CX, Yu JS, Yu L, Yu SP, Yuan CZ, Yuan WL, Yuan Y, Zafar AA, Zallo A, Zeng Y, Zhang BX, Zhang BY, Zhang CC, Zhang DH, Zhang HH, Zhang HY, Zhang J, Zhang JG, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang L, Zhang SH, Zhang TR, Zhang XJ, Zhang XY, Zhang Y, Zhang YH, Zhang YS, Zhang ZP, Zhang ZY, Zhao G, Zhao HS, Zhao JW, Zhao KX, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao TC, Zhao XH, Zhao YB, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zheng ZP, Zhong B, Zhong J, Zhou L, Zhou XK, Zhou XR, Zhu C, Zhu K, Zhu KJ, Zhu SH, Zhu XL, Zhu XW, Zhu YM, Zhu YS, Zhu ZA, Zhuang J, Zou BS, Zou JH, Zuo JX. First observation of the M1 transition ψ(3686)→γη(c)(2S). PHYSICAL REVIEW LETTERS 2012; 109:042003. [PMID: 23006078 DOI: 10.1103/physrevlett.109.042003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2012] [Indexed: 06/01/2023]
Abstract
Using a sample of 106×10(6) ψ(3686) events collected with the BESIII detector at the BEPCII storage ring, we have made the first measurement of the M1 transition between the radially excited charmonium S-wave spin-triplet and the radially excited S-wave spin-singlet states: ψ(3686)→γη(c)(2S). Analyses of the processes ψ(3686)→γη(c)(2S) with η(c)(2S)→K(S)(0)K(±)π(∓) and K(+)K(-)π(0) give an η(c)(2S) signal with a statistical significance of greater than 10 standard deviations under a wide range of assumptions about the signal and background properties. The data are used to obtain measurements of the η(c)(2S) mass (M(η(c)(2S))=3637.6±2.9(stat)±1.6(syst) MeV/c(2)), width (Γ(η(c)(2S))=16.9±6.4(stat)±4.8(syst) MeV), and the product branching-fraction (B(ψ(3686)→γη(c)(2S))×B(η(c)(2S)→KKπ)=(1.30±0.20(stat)±0.30(syst))×10(-5)). Combining our result with a BABAR measurement of B(η(c)(2S)→KKπ), we find the branching fraction of the M1 transition to be B(ψ(3686)→γη(c)(2S))=(6.8±1.1(stat)±4.5(syst))×10(-4).
Collapse
|
133
|
Nuño M, Mukherjee D, Elramsisy A, Nosova K, Lad SP, Boakye M, Yu JS, Black KL, Patil CG. Racial and Gender Disparities and the Role of Primary Tumor Type on Inpatient Outcomes Following Craniotomy for Brain Metastases. Ann Surg Oncol 2012; 19:2657-63. [DOI: 10.1245/s10434-012-2353-z] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2011] [Indexed: 11/18/2022]
|
134
|
Pinilla C, Judkowski V, Bunying A, Ji J, Li Z, Bender J, Yu JS. Abstract 510: Identification and characterization of immunogenic epitopes from CD133 and their potential for use to immunologically target cancer stem cells. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CD133 is a marker that identifies cancer stem cells (CSC) on many solid tumors and its expression has been correlated with shortened survival. Although expressed on many normal tissues and stem cells, CD133 is overexpressed on CSC and normal SC are negative or express low levels of MHC making them less sensitive to recognition by CD8+ cytotoxic T lymphocytes (CTL). Potential CTL epitopes were identified by algorithms to predict binding to HLA-A2. Binding studies showed high affinity binding and low off rates for four candidate epitopes. CTL induction studies using IL-12 secreting dendritic cells to stimulate CD8+ T cells evaluated the immunogenicity of the candidate peptides after three or four weekly in vitro stimulations. Multimer and IFNγ responses were observed with CD133-753, 405 and 708 epitopes. Subsequent studies demonstrated killing of T2 cells loaded with peptide. To evaluate the potential for autoimmunity, mouse homolog peptides of the 753 and 405 epitopes that were shown to have high affinity binding to human HLA-A2 were used to immunize HLA-A2 transgenic mice (9CB6F1-Tg (HLA-A*0201/H2-Kb) A*0201). Mice were immunized 3 times at 3 week intervals in IFA + HBV helper peptide and spleens were harvested 2 weeks after the last immunization and stimulated in vitro for one week with peptide pulsed LPS stimulated- APC. An additional group was sacrificed 6 weeks after the last immunization and studied. IFNγ ELISpot assays showed immune responses to the 753 and 405 peptides in 35% and 40% of mice. Organs, including heart, lung, liver, kidney, stomach, intestine, brain, bone marrow, gonads, and eyes from mice with immune responses were found to be negative for lymphocytic infiltrations supporting a lack of autoimmunity related to the immune response to these peptides. Together these studies support the safety and immunogenicity of these peptides as a potential vaccine to target CD133 cancer stem cells.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 510. doi:1538-7445.AM2012-510
Collapse
|
135
|
Carico C, Nuño M, Mukherjee D, Elramsisy A, Dantis J, Hu J, Rudnick J, Yu JS, Black KL, Bannykh SI, Patil CG. Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS One 2012; 7:e33684. [PMID: 22479427 PMCID: PMC3315579 DOI: 10.1371/journal.pone.0033684] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2011] [Accepted: 02/15/2012] [Indexed: 12/25/2022] Open
Abstract
INTRODUCTION Pre-temozolomide studies demonstrated that loss of the tumor suppressor gene PTEN held independent prognostic significance in GBM patients. We investigated whether loss of PTEN predicted shorter survival in the temozolomide era. The role of PTEN in the PI3K/Akt pathway is also reviewed. METHODS Patients with histologically proven newly diagnosed GBM were identified from a retrospective database between 2007 and 2010. Cox proportional hazards analysis was used to calculate the independent effects of PTEN expression, age, extent of resection, Karnofsky performance scale (KPS), and treatment on overall survival. RESULTS Sixty-five percent of patients were men with median age of 63 years, and 70% had KPS≥80. Most patients (81%) received standard treatment (temozolomide with concurrent radiation). A total of 72 (47%) patients had retained PTEN expression. Median overall survival (OS) was 19.1 months (95% CI: 15.0-22.5). Median survival of 20.0 months (95% CI: 15.0-25.5) and 18.2 months (95% CI: 13.0-25.7) was observed in PTEN retained and PTEN loss patients, respectively (p = .71). PTEN loss patients were also found to have amplifications of EGFR gene more frequently than patients with retained PTEN (70.8% vs. 47.8%, p = .01). Multivariate analysis showed that older age (HR 1.64, CI: 1.02-2.63, p = .04), low KPS (HR 3.57, CI: 2.20-5.79, p<.0001), and lack of standard treatment (HR 3.98, CI: 2.38-6.65, p<.0001) yielded worse survival. PTEN loss was not prognostic of overall survival (HR 1.31, CI: 0.85-2.03, p = .22). CONCLUSIONS Loss of expression of PTEN does not confer poor overall survival in the temozolomide era. These findings imply a complex and non-linear molecular relationship between PTEN, its regulators and effectors in the tumorigenesis of glioblastoma. Additionally, there is evidence that temozolomide may be more effective in eradicating GBM cancer cells with PTEN loss and hence, level the outcomes between the PTEN retained and loss groups.
Collapse
|
136
|
Xu Q, Yuan X, Yu JS. Glioma stem cell research for the development of immunotherapy. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2012; 746:216-25. [PMID: 22639171 DOI: 10.1007/978-1-4614-3146-6_17] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Malignant gliomas are characterized by its invasiveness and dissemination, resulting in frequent tumor recurrence after surgical resection and/or conventional chemotherapy and radiation therapy. Various strategies of active and passive immunotherapy in developing stages have shown promise to increase patient survival time with little severe side effects. In recent years, glioma stem cells had been isolated from patient tumor specimens. Biochemical and biological characterization of these cancer initiating cells implicated their critical roles in cancer growth, malignancy and resistance to conventional treatments. In this chapter, we review recent research progress in targeting brain cancer using neural stem cells delivered cytotoxic factors and immune regulation factor, dendritic cell based vaccination, with special emphasis on targeting glioma stem cells. We present evidence supporting the notion that glioma stem cells may be preferred therapeutic targets not only for conventional therapies, but also for immunotherapies. Future progress in glioma stem cell research may fundamentally improve the prospect of malignant glioma treatments.
Collapse
|
137
|
Li Z, Lee JW, Mukherjee D, Ji J, Jeswani SP, Black KL, Yu JS. Immunotherapy targeting glioma stem cells--insights and perspectives. Expert Opin Biol Ther 2011; 12:165-78. [PMID: 22200324 DOI: 10.1517/14712598.2012.648180] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
INTRODUCTION Glioblastoma multiforme (GBM) is the most aggressive and lethal primary malignant brain tumor. Although progress has been made in current conventional therapies for GBM patients, the effect of these advances on clinical outcomes has been disappointing. Recent research into the origin of cancers suggest that GBM cancer stem cells (GSC) are the source of initial tumor formation, resistance to current conventional therapeutics and eventual patient relapse. Currently, there are very few studies that apply immunotherapy to target GSC. AREAS COVERED CD133, a cell surface protein, is used extensively as a surface marker to identify and isolate GSC in malignant glioma. We discuss biomarkers such as CD133, L1-cell adhesion molecule (L1-CAM), and A20 of GSC. We review developing novel treatment modalities, including immunotherapy strategies, to target GSC. EXPERT OPINION There are very few reports of preclinical studies targeting GSC. Identification and validation of unique molecular signatures and elucidation of signaling pathways involved in survival, proliferation and differentiation of GSC will significantly advance this field and provide a framework for the rational design of a new generation of antigen-specific, anti-GSC immunotherapy- and nanotechnology-based targeted therapyies. Combined with other therapeutic avenues, GSC-targeting therapies may represent a new paradigm to treat GBM patients.
Collapse
|
138
|
Lee BS, Nalla AK, Stock IR, Shear TC, Black KL, Yu JS. Corrigendum to “Oxidative stimuli-responsive nanoprodrug of camptothecin kills glioblastoma cells” [Bioorg. Med. Chem. Lett. 20 (2010) 5262]. Bioorg Med Chem Lett 2011. [DOI: 10.1016/j.bmcl.2011.04.113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
139
|
Milanesi A, Lee JW, Xu Q, Perin L, Yu JS. Differentiation of nestin-positive cells derived from bone marrow into pancreatic endocrine and ductal cells in vitro. J Endocrinol 2011; 209:193-201. [PMID: 21330336 DOI: 10.1530/joe-10-0344] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Promising results of pancreatic islet transplantation to treat type 1 diabetes mellitus, combined with severe shortage of donor pancreata, have spurred efforts to generate pancreatic islet-like cells and insulin-producing β-cells from various progenitor populations. In this study, we show for the first time that multipotent nestin-positive stem cells selected from rat bone marrow can be differentiated into pancreatic ductal and insulin-producing β-cells in vitro. We report an effective multistep protocol in a serum-free system, which could efficiently induce β-cell differentiation from multipotent nestin-positive bone marrow stem cells. To enhance the induction and differentiation toward pancreatic lineage we used trichostatin A, an important regulator of chromatin remodeling, and 5-aza 2' deoxycytidine, an inhibitor of DNA methylase. All-trans retinoic acid was then utilized to promote pancreatic differentiation. We sequentially induced important transcription factor genes, such as Pdx1, Ngn3, and Pax6, following the in vivo development timeline of the pancreas in rats. Furthermore, in the final stage with the presence of nicotinamide, the induced cells expressed islet and ductal specific markers. The differentiated cells not only expressed insulin and glucose transporter 2, but also displayed a glucose-responsive secretion of the hormone. Our results delineate a new model system to study islet neogenesis and possible pharmaceutical targets. Nestin-positive bone marrow stem cells may be therapeutically relevant for β-cell replacement in type 1 diabetes.
Collapse
|
140
|
Lee BS, Nalla AK, Stock IR, Shear TC, Black KL, Yu JS. Oxidative stimuli-responsive nanoprodrug of camptothecin kills glioblastoma cells. Bioorg Med Chem Lett 2010; 20:5262-8. [PMID: 20655220 DOI: 10.1016/j.bmcl.2010.06.144] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2010] [Revised: 06/28/2010] [Accepted: 06/29/2010] [Indexed: 11/18/2022]
Abstract
The purpose of this study was to prepare and characterize nanometer-sized prodrug (nanoprodrug) of camptothecin. The camptothecin prodrug was synthesized using tetraethylene glycol spacer linked via carbonate bond to camptothecin and via ester bond to alpha-lipoic acid. The nanoprodrug was prepared through the spontaneous emulsification mechanism using the mixture of camptothecin prodrug and alpha-tocopherol which served as a structural matrix. The nanoprodrug was activated readily by porcine liver esterase and, with a much slower rate, by hydrolytic degradation. Upon longterm storage, the alpha-lipoic acid moiety of the camptothecin prodrug gradually oxidized without loss of structural integrity and therapeutic efficacy. Interestingly, the hydrolytic activation was negligible before the oxidation, but was significantly accelerated after the oxidation of the alpha-lipoic acid moiety, suggesting an oxidative stimuli-responsive activation of the prodrug. The camptothecin nanoprodrug was found to possess significant inhibitory effect on the proliferation of U87-MG glioma cells with an IC(50) of 20 nM.
Collapse
|
141
|
Xu Q, Liu G, Yuan X, Xu M, Wang H, Ji J, Konda B, Black KL, Yu JS. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2010; 27:1734-40. [PMID: 19536809 DOI: 10.1002/stem.102] [Citation(s) in RCA: 154] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, with current treatment remaining palliative. Immunotherapies harness the body's own immune system to target cancers and could overcome the limitations of conventional treatments. One active immunotherapy strategy uses dendritic cell (DC)-based vaccination to initiate T-cell-mediated antitumor immunity. It has been proposed that cancer stem-like cells (CSCs) may play a key role in cancer initiation, progression, and resistance to current treatments. However, whether using human CSC antigens may improve the antitumor effect of DC vaccination against human cancer is unclear. In this study, we explored the suitability of CSCs as sources of antigens for DC vaccination again human GBM, with the aim of achieving CSC-targeting and enhanced antitumor immunity. We found that CSCs express high levels of tumor-associated antigens as well as major histocompatibility complex molecules. Furthermore, DC vaccination using CSC antigens elicited antigen-specific T-cell responses against CSCs. DC vaccination-induced interferon-gamma production is positively correlated with the number of antigen-specific T cells generated. Finally, using a 9L CSC brain tumor model, we demonstrate that vaccination with DCs loaded with 9L CSCs, but not daughter cells or conventionally cultured 9L cells, induced cytotoxic T lymphocytes (CTLs) against CSCs, and prolonged survival in animals bearing 9L CSC tumors. Understanding how immunization with CSCs generates superior antitumor immunity may accelerate development of CSC-specific immunotherapies and cancer vaccines.
Collapse
|
142
|
Ji J, Black KL, Yu JS. Glioma stem cell research for the development of immunotherapy. Neurosurg Clin N Am 2009; 21:159-66. [PMID: 19944974 DOI: 10.1016/j.nec.2009.08.006] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Glioma, especially high-grade glioblastoma multiforme (GBM), is the most common and aggressive type of brain tumor, accounting for about half of all the primary brain tumors. Despite continued advances in surgery, chemotherapy, and radiotherapy, the clinical outcomes remain dismal. The 2-year survival rate of GBM is less than 30%. Better understanding of GBM biology is needed to develop novel therapies. Recent studies have demonstrated the existence of a small subpopulation of cells with stemlike features called cancer stem cells (CSCs). These GBM CSCs are self renewable and highly tumorigenic. They not only are chemo-radio resistant but also often contain multidrug resistance genes and drug transporter genes. These characteristics enable GBM CSCs to survive standard cytotoxic therapies. Among GBM CSCs, CD133(+) cells are a well-defined population and are prospectively isolated by their cell-surface marker. Increasing data show that the presence of CD133(+) CSCs highly correlates with patient survival, making these cells an ideal immunotherapy target population. The authors have reviewed recent studies related with GBM CSCs (particularly CD133(+) CSCs) and the novel therapeutic strategies targeting these cells.
Collapse
|
143
|
Song YM, Choi ES, Yu JS, Lee YT. Light-extraction enhancement of red AlGaInP light-emitting diodes with antireflective subwavelength structures. OPTICS EXPRESS 2009; 17:20991-20997. [PMID: 19997337 DOI: 10.1364/oe.17.020991] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
We demonstrate the enhancement of light extraction in 633 nm AlGaInP light-emitting diodes (LEDs) with antireflective subwavelength structures (SWS). From the contour plots by the rigorous coupled wave analysis method, it is found that the reduction of the internal reflection strongly depends on the period of SWS. The Ag nanoparticles formed by thermal dewetting were used as an etch mask for dry etch process to fabricate antireflective SWS on the LED surface. The tapered pillars on the GaP were fabricated, on average, with distances below 200 nm, satisfying the required antireflection condition at the emission wavelength. The improvement in light output power by approximately 26.4% was achieved for the fabricated AlGaInP LEDs with SWS compared to the conventional LEDs due to a strongly reduced Fresnel internal reflection at the GaP/air interface. The improved directionality in the far-field pattern was also obtained due to the directional light extraction enhancement.
Collapse
|
144
|
Song YM, Jeong BK, Na BH, Chang KS, Yu JS, Lee YT. High-speed characteristics of vertical cavity surface emitting lasers and resonant-cavity-enhanced photodetectors based on intracavity-contacted structure. APPLIED OPTICS 2009; 48:F11-F17. [PMID: 19724307 DOI: 10.1364/ao.48.000f11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
We fabricated vertical cavity surface emitting lasers (VCSELs) and resonant-cavity-enhanced photodetectors (RCE-PDs) with GaAs/AlGaAs distributed Bragg reflectors (DBRs), operating at lambda approximately 980 nm, based on an intracavity-contacted structure. The top-DBR mesa diameter of the VCSELs was optimized to 18 microm in terms of slope efficiency, differential series resistance, and 3 dB bandwidth. For VCSELs with an oxide aperture of 4.5 microm and a top-DBR mesa diameter of 18 microm, the threshold current was about 1.2 mA, exhibiting maximum output power of approximately 3.49 mW (at 20 degrees C) with good uniformity. The effect of the overetching in the outermost layer of RCE-PDs on the device performance was also investigated. For RCE-PDs based on the VCSEL structure, a peak responsivity of 0.44 A/W (at lambda approximately 979.7 nm) with a spectral width of approximately 3 nm and a dark current of 68 pA under a bias voltage of -5 V at 20 degrees C was obtained. The maximum 3 dB bandwidths of approximately 11.5 GHz with a modulation current efficiency factor of 5.6 GHz/mA(1/2) at -7 mA and 9 GHz at -7 V were achieved for VCSELs and RCE-PDs, respectively.
Collapse
|
145
|
Xu Q, Yuan X, Xu M, McLafferty F, Hu J, Lee BS, Liu G, Zeng Z, Black KL, Yu JS. Chemokine CXC receptor 4--mediated glioma tumor tracking by bone marrow--derived neural progenitor/stem cells. Mol Cancer Ther 2009; 8:2746-53. [PMID: 19723878 DOI: 10.1158/1535-7163.mct-09-0273] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Malignant gliomas manifest frequent tumor recurrence after surgical resection and/or other treatment because of their nature of invasiveness and dissemination. The recognized brain tumor-tracking property of neural progenitor/stem cells opened the possibility of targeting malignant brain tumors using neural progenitor/stem cells. We and others have previously shown that fetal neural progenitor/stem cells can be used to deliver therapeutic molecules to brain tumors. Our recent work has further shown that gene delivery by bone marrow-derived neural progenitor/stem cells achieves therapeutic effects in a glioma model. In this study, we isolate and characterize bone marrow-derived neural progenitor/stem cells, which also express the chemokine receptor chemokine CXC receptor 4 (CXCR4). We show that CXCR4 is required for their chemotaxis and extracellular matrix invasion against a gradient of glioma soluble factors. Furthermore, beta-galactosidase-labeled bone marrow-derived neural progenitor/stem cells implanted in the contralateral side of the brain were shown to track gliomas as early as day 1 and increased through days 3 and 7. Intracranial glioma tracking by bone marrow-derived neural progenitor/stem cells is significantly inhibited by preincubation of bone marrow-derived neural progenitor/stem cells with a blocking anti-CXCR4 antibody, suggesting a CXCR4-dependent tracking mechanism. Glioma tracking bone marrow-derived neural progenitor/stem cells were found to express progenitor/stem cell markers, as well as CXCR4. Although bromodeoxyuridine incorporation assays and proliferating antigen staining indicated that tumor tracking bone marrow-derived neural progenitor/stem cells were mostly nonproliferating, these cells survive in the local tumor environment with little apoptosis. Elucidating the molecular mechanism of brain tumor tracking by adult source stem cells may provide basis for the development of future targeted therapy for malignant brain tumors.
Collapse
|
146
|
Yu JS, Rudnick J, Chu RM, Mazer M, Wang H, Serrano N, Francisco M, Wheeler CJ, Singh M, Black KL, Phuphanich S. A Phase I Trial of Tumor Associated Antigen-Pulsed Dendritic Cell Immunotherapy for Patients with Glioblastoma. Neurosurgery 2009. [DOI: 10.1227/01.neu.0000358747.32411.f4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
147
|
Yu JS, Shim JH, Chung JJ, Kim JH, Kim KW. Double contrast-enhanced MRI of viral hepatitis-induced cirrhosis: correlation of gross morphological signs with hepatic fibrosis. Br J Radiol 2009; 83:212-7. [PMID: 19505965 DOI: 10.1259/bjr/70974553] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The purpose of this study was to evaluate the diagnostic ability of the expanded gallbladder fossa and right posterior hepatic notch signs for hepatic fibrosis determined by double contrast-enhanced MRI. For patients with chronic viral hepatitis B (n = 96) or hepatitis C (n = 13) who underwent gadopentate dimeglumine-enhanced dynamic MRI followed by ferucarbotran-enhanced gradient-echo imaging, the degree of parenchymal fibrosis was categorised into three groups based on the extent of reticulation and nodularity: (1) pre-cirrhotic or minimal fibrosis; (2) mild to moderate fibrosis; (3) advanced cirrhosis. Each group was evaluated for the presence of a sharp notch in the posterior-medial surface of the right lobe of the liver and expanded gallbladder fossa. The expanded gallbladder fossa sign gradually increased with an increasing degree of fibrosis (Group 1, 50%; Group 2, 61%; Group 3, 78%), and there was no significant difference (p>0.5) between hepatitis B (67%) and C (73%). In the case of the right posterior hepatic notch sign, only 6% of Group 1 and Group 2 patients were positive; 27% of hepatitis B patients and 90% of hepatitis C patients in Group 3 exhibited the sign (p<0.05). Owing to its low prevalence, even in advanced cirrhosis, the right posterior hepatic notch sign is of little value in the diagnosis of cirrhosis due to chronic hepatitis B virus infection, whereas an expanded gallbladder fossa could be used as a non-specific indicator of early fibrosis before the gross appearance of advanced hepatic fibrosis.
Collapse
|
148
|
Lee BS, Yuan X, Xu Q, McLafferty FS, Petersen BA, Collette JC, Black KL, Yu JS. Stimuli-responsive antioxidant nanoprodrugs of NSAIDs. Int J Pharm 2009; 372:112-24. [PMID: 19166922 DOI: 10.1016/j.ijpharm.2008.12.037] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2008] [Revised: 12/20/2008] [Accepted: 12/26/2008] [Indexed: 11/16/2022]
Abstract
A novel group of alpha-lipoic acid-containing hydrophobic prodrugs of non-steroidal anti-inflammatory drugs (NSAIDs) was synthesized and transformed into nanometer-sized prodrugs (nanoprodrugs). Three NSAIDs, indomethacin, ibuprofen and naproxen were linked to alpha-lipoic acid via tetraethylene glycol through hydrolytically degradable ester bonds. The three bifunctional derivatives were dissolved in organic solvents and capable of forming stable nanoprodrugs upon addition of the organic solutions into aqueous phase through the spontaneous emulsification mechanism. Antioxidant property and stimuli-responsiveness of the nanoprodrugs were demonstrated by hypochlorous acid (HOCl) scavenging followed by oxidative destabilization of the nanoprodrugs. The effect of varying NSAIDs on the in vitro hydrolytic prodrug activation catalyzed by porcine liver esterase was investigated by monitoring the rates of NSAIDs hydrolysis from the nanoprodrugs. The remarkable feature of these nanoprodrugs is that despite the highly hydrophobic nature of the derivatives NSAIDs were readily hydrolyzed enzymatically from the nanoprodrugs. Furthermore, the rate of hydrolysis was higher when the nanoprodrugs were oxidized and destabilized upon HOCl scavenging suggesting an enhanced activation of the nanoprodrugs in the oxidative environment.
Collapse
|
149
|
Abstract
The identification of a subpopulation of brain tumor cells with potent tumorigenic capacity strengthens the cancer stem cell hypothesis of the origin of the tumors that has recently attracted the attention of many researchers. Reports have been published on the identification of tumor cells with stem cells characteristics in different types of tumors (acute myelogenic leukemia, breast cancer, prostate cancer, bone sarcomas, liver cancer, and melanomas). We and other groups have previously reported the isolation of cancer stem cells from adult glioblastoma multiforme. These cells express stem cell markers, and when differentiated they express glial and neuronal markers. In vivo they give a tumor that recapitulates the characteristics of the tumor in the patient. More recently we have isolated tumor stem-like cells also from benign tumors like pituitary adenomas. Cells derived from pituitary adenomas are able to grow as floating aggregates resembling the neurospheres (typical of normal stem cells) in a medium supplemented by growth factors (EGF and bFGF). The immunocytochemical analysis revealed that pituitary tumor stem-like cells are positives for nestin and, when grown for ten days in differentiation medium they express GFAP, BIII tubulin, and S-100. In vitro tumor stem-like cells derived from a patient with a somatotroph adenoma showed high production of growth hormone and prolactin, while cells derived from the same patient but grown in presence of fetal bovine serum showed no production of hormones.
Collapse
|
150
|
Xu Q, Yuan X, Liu G, Black KL, Yu JS. Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas. Stem Cells 2008; 26:3018-26. [PMID: 18787206 DOI: 10.1634/stemcells.2008-0459] [Citation(s) in RCA: 87] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The identification of brain tumor stem-like cells (BTSCs) has implicated a role of biological self-renewal mechanisms in clinical brain tumor initiation and propagation. The molecular mechanisms underlying the tumor-forming capacity of BTSCs, however, remain unknown. Here, we have generated molecular signatures of glioblastoma multiforme (GBM) using gene expression profiles of BTSCs and have identified both Sonic Hedgehog (SHH) signaling-dependent and -independent BTSCs and their respective glioblastoma surgical specimens. BTSC proliferation could be abrogated in a pathway-dependent fashion in vitro and in an intracranial tumor model in athymic mice. Both SHH-dependent and -independent brain tumor growth required phosphoinositide 3-kinase-mammalian target of rapamycin signaling. In human GBMs, the levels of SHH and PTCH1 expression were significantly higher in PTEN-expressing tumors than in PTEN-deficient tumors. In addition, we show that hyperactive SHH-GLI signaling in PTEN-coexpressing human GBM is associated with reduced survival time. Thus, distinct proliferation signaling dependence may underpin glioblastoma propagation by BTSCs. Modeling these BTSC proliferation mechanisms may provide a rationale for individualized glioblastoma treatment.
Collapse
|